Symptom presentation
Symptoms that prompted the patient to seek hospital care are presented in
Table 2. Participants reported up to 23 symptoms, with a mean of 6.13 (SD = 4.24). Chest pain was experienced by approximately 68% of male and female participants. The most frequent symptoms reported were chest pain behind the breast bone, sweating, shortness of breath, and chest pain in the left arm. Gender differences in all 25 symptoms were tested using Pearson's χ
2 with a Bonferonni adjustment (.05/25 = .002). There were no significant gender differences in any of the most frequently reported cardiac symptoms. Where gender differences did occur, symptoms experienced in the 30 days before the coronary event were more prevalent in females (e.g., pain/pressure in the right side of their back, vomiting) than males. This is likely due to the fact that women (mean = 7.44, SD = 4.62) reported significantly more symptoms than males (mean = 5.62, SD = 3.98;
t(480) = −4.33,
p < .001).
Table 2Self-reported cardiac symptom presentation by gender
Thrombolysis
Two hundred eight participants (44.1%) were thrombolyzed. Patient contraindications to thrombolysis are presented in
Table 4. Of the patients for whom there were no contraindications to thrombolysis (i.e., diagnostic ECG, arrived without delay, no risk of bleeding;
n = 331), thrombolytic was given on admission to 208 patients (62.8%), but not to 123 patients (37.2%). There was a significant gender difference in administration of thrombolysis among those patients with an MI who were eligible for such treatment (χ
2 (1) = 10.12,
p = .001). Fifty females (50.0%) and 158 males (68.4%) received this treatment. There was also a significant gender difference in reasons that thrombolysis was not administered, χ
2 (6) = 40.98,
p < .001. Females were less likely to receive the drug, and at the same time less likely to have a recorded explanation for contraindication than males.
Table 4Frequency of nurse-reported thrombolysis administration and contraindication by gender
Note: There were no data available for three females and seven males.
Two Kruskal-Wallis one-way ANOVAs were performed examining thrombolysis: whether it was administered, not administered with recorded contraindication, or not administered without recorded contraindication (see
Table 5). One was performed using the male sample, the other with the female sample. Independent variables were fourfold: age, family income, symptom onset to arrival time, and time from hospital arrival to diagnostic ECG. Tests of homogeneity of variance revealed that age (Levene's statistic = .82,
p = .44) and family income (Levene's statistic = .68,
p = .51) met this assumption; however, onset to arrival time (Levene's statistic = 31.96,
p < .001) and hospital arrival to ECG time (Levene's statistic = 3.39,
p = .04) did not. Therefore, where Kruskal-Wallis was significant, post-hoc LSD tests were used where assumptions were met and Games-Howell was used where assumptions were violated.
Table 5Median age, family income, and prehospital and hospital delay in minutes based on gender, and nurse recording regarding thrombolysis administration
Among males, there was a significant difference in thrombolysis administration based on family income (χ2 (2) = 7.30, p = .03), onset to arrival time (χ2 (2) = 17.72, p < .001), and arrival to ECG time (χ2 (2) = 39.90, p < .001). Post-hoc LSD tests revealed that male MI patients who received thrombolysis had significantly higher family income than those who did not receive thrombolysis due to a legitimate contraindication (p = .006), and Games-Howell revealed that males who received thrombolysis had significantly shorter delay from onset to arrival than patients with a legitimate contraindication (p < .001). For females, there was a significant difference in thrombolysis administration based on age (χ2 (2) = 5.88, p = .05), symptom onset to hospital arrival time (χ2 (2) = 9.58, p = .01), and arrival to ECG time (χ2 (2) = 7.85, p = .02). Post-hoc LSD tests revealed that female MI patients who received thrombolysis were significantly younger than those who did not receive thrombolysis due to a legitimate contraindication (p = .02), and younger than those for whom there was no contraindication provided for nonadministration (p = .04). Based on Games-Howell, females who received thrombolysis had significant shorter delay from onset to arrival than patients with a legitimate contraindication (p = .01).